RBC Capital keeps an Outperform rating on QuidelOrtho with an $81 price target after the company withdrew its original Savanna RVP4+ assay from FDA 510(k) submission. Management told RBC they have been working in parallel to address issues seen in the prior panel and will be resubmitting the Savanna RVP4+ assay FDA 510(k) submission with approval expected in time for the 2024/2025 respiratory season, the analyst tells investors in a research note. The firm says the company also mentioned that there are no updates to the Savanna’s 2024 guidance. RBC says the news does not change its thesis on QuidelOrtho.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue